Huangqiyenins G – J, Four New 9,10-Secocycloartane (= 9,19-Cyclo-9,10secolanostane) Triterpenoidal Saponins from Astragalus membranaceus BUNGE Leaves

by Hai-Xue Kuang*^a), Qiu-Hong Wang^a), Bing-You Yang^a), Zhi-Bin Wang^a), Yoshihito Okada^b), and Tohru Okuyama^b)

 ^a) Key Laboratory of Chinese Materia Medica, Heilongjiang University of Chinese Medicine, Ministry of Education, No. 24 Heping Road, Xiangfang District, Harbin 150040, P. R. China (phone: +86-451-82193001; fax: +86-451-82110803; e-mail: hxkuang@hotmail.com)
 ^b) Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan

Four new 9,10-secocycloartane (=9,19-cyclo-9,10-secolanostane) triterpenoidal saponins, named huangqiyenins G – J (1–4, resp.), were isolated from *Astragalus membranaceus* BUNGE leaves. The acid hydrolysis of 1–4 with 1M aqueous HCl yielded D-glucose, which was identified by GC analysis after treatment with L-cysteine methyl ester hydrochloride. The structures of 1–4 were established by detailed spectroscopic analysis as $(3\beta,6\alpha,10\alpha,16\beta,24E)$ -3,6-bis(acetyloxy)-10,16-dihydroxy-12-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside (1), $(3\beta,6\alpha,10\alpha,24E)$ -3,6-bis(acetyloxy)-10-hydroxy-12,16-dioxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside (2), $(3\beta,6\alpha,9\alpha,10\alpha,16\beta,24E)$ -3,6-bis(acetyloxy)-9,10,16-trihydroxy-9,19-cyclo-9,10-secolanosta-11,24-dien-26-yl β -D-glucopyranoside (3), and $(3\beta,6\alpha,10\alpha,24E)$ -3,6-bis(acetyloxy)-10-hydroxy-16-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside (4).


Introduction. – Astragalus membranaceus BUNGE belongs to the family Leguminosae and has long been one of the most important tonic herbs used in traditional Chinese medicine. Pharmacological investigations demonstrated that extracts of the leaves possess biological activities, including antioxidation, anti-aging, and anti-inflammatory activity [1], and protection against pancreatic injury [2]. The dried leaves of *A. membranaceus* (named beiqishengcha) has been authorized as a functional food by the *State Food and Drug Administration* of P. R. China in 1998.

Known biologically active components of *A. membranaceus* are triterpenoidal saponins, flavonoids, and polysaccharides. Chemical studies on *Astragalus* saponins have reported the presence of cycloartane-type triterpenoid glycosides which were found to exert many biological activities (*e.g.*, hepatoprotection, cardioprotection, antidiabetic nephropathy, anti-inflammatory, gastroprotection, and neuroprotection against ischemic brain injury) [3-8].

In the earlier investigations of *A. membranaceus* leaves, we have reported four cycloartane-type and two secocycloartane triterpenoid saponins named huangqiyenins A-F [9–12] (cycloartane = 9,19-cyclolanostane). As a continuing phytochemical study on this natural medicine, we further isolated four new 9,10-secocycloartane (=9,19-cyclo-9,10-secolanostane = 9(10)a-homo-19-norlanostane) triterpenoidal saponins, huangqiyenins G-J (1–4, resp.). It is worth mentioning that 9,10-secocycloartane tanes are less common than their cycloartane counterparts. They represent a small group of compounds comprising *ca.* 20 representatives in the Ranunculaceae,

© 2011 Verlag Helvetica Chimica Acta AG, Zürich

Buxaceae, and Leguminosae families [13-15]. This article deals with the isolation and structure elucidation of these newly isolated triterpenoids.



Results and Discussion. - Compound 1, named huangqiyenin G, was obtained as a white amorphous powder (MeOH). The molecular formula was determined as $C_{40}H_{62}O_{13}$ by HR-FAB-MS ([M+Na]⁺ at m/z 773.4087), indicating ten degrees of unsaturation. The ¹H-NMR spectrum of **1** (*Table 1*) showed seven Me s at $\delta(H)$ 0.91, $1.08, 1.20, 1.55, 1.78, 2.06, \text{ and } 2.08, \text{ a Me } d \text{ at } \delta(\text{H}) 1.38 (J = 6.5 \text{ Hz}), \text{ an olefinic H-atom}$ s at $\delta(H)$ 5.92, and an olefinic H-atom t at $\delta(H)$ 5.72 (J = 6.4 Hz). No signals due to Hatoms of a cyclopropane ring were observed. The typical downfield CH d at $\delta(H)$ 4.90 (J = 7.8 Hz) was assigned to the anomeric H-atom of the β -D-glucopyranosyl moiety. The acid hydrolysis of 1 with 1M aqueous HCl yielded D-glucose, which was identified by GC analysis after treatment with L-cysteine methyl ester hydrochloride in pyridine [16]. The ¹³C-NMR data (*Table 2*) showed the presence of 40 C-atoms that were sorted by a DEPT experiment as eight Me, nine CH_2 , and 14 CH groups, as well as nine quaternary C-atoms, including four olefinic C-atoms at $\delta(C)$ 128.3, 129.5, 131.9, and 157.6, and three C=O groups at δ (C) 170.4, 170.5, and 203.8. The ¹H- and ¹³C-NMR signals were assigned by HSQC, ¹H,¹H-COSY, and HSQC-TOCSY data. The full connectivity was deduced from the HMBC data (Fig.). In particular, the key longrange correlations $H_a - C(19)/C(5)$, C(8), C(9), C(10), and C(11), and $H_a - C(19)/C(8)$, C(9), C(10), and C(11) showed that the $CH_2(19)$ group must be located between C(9)and C(10), and the coupling constants J = 14.7 and 1.2 Hz of H_a-C(19) indicated that C(19) was connected to two quaternary C-atoms (C(9) and C(10)), and H_a-C(19) showed allylic coupling with H–C(11). The HMBCs Me(18)/C(12), C(13), C(14), and C(17), and H-C(11)/C(8), C(9), C(12), C(13), and C(19) indicated that the C=O group at $\delta(C)$ 203.8 must be located at C(12). Furthermore, the correlation from the

¹⁾ Trivial atom numbering; for systematic names, see Exper. Part.

anomeric H-atom of the glucosyl moiety at $\delta(H)$ 4.90 to $\delta(C)$ 75.2 could also be observed, which confirmed that the glucosyloxy group should be attached to C(26). In addition, in the HMBC spectrum of **1**, H–C(3) and H–C(6) showed connectivity with the C=O of the AcO groups at $\delta(C)$ 170.4 and 170.5, respectively. Compound **1** was thus determined to represent a 9,19-cyclo-9,10-secolanostane-type triterpenoid with two Ac groups and a glucosyl group.




Figure. Key HMBC ($H \rightarrow C$) and ¹H, ¹H-COSY (—) features of **1** and **3**

The relative configuration of **1** was determined on the basis of ${}^{1}H$, ${}^{1}H$ -coupling constants, NOESY experiments, and comparison of NMR data with those of huangqiyenin F [12], a compound previously isolated from A. membranaceus which possessed a (24E) side-chain moiety. In particular, the ¹³C-NMR data of the side chain were almost identical in both compounds, and the correlations between H-C(23) and Me(27) were observed in the NOESY experiment, which enabled the assignment of the C(24)=C(25) bond configuration as (E) in **1**. The configuration at C(3) of **1** could be assigned as β , according to the coupling constant of H–C(3) at δ (H) 4.93 (dd, J = 10.4, 2.0 Hz). The NOESY correlations Me(30)/H-C(6), Me(29)/H-C(5), Me(29)/ H-C(3), Me(28)/H-C(16), Me(28)/H-C(17), Me(18)/H-C(8), H-C(5)/H-C(3), $H-C(6)/H_{\beta}-C(19)$, H-C(6)/H-C(8) were observed. From these data, H-C(3), H–C(5), H–C(16), H–C(17), and H_a–C(19) could be placed in α -position, H–C(6), and H–C(8), and H_{β}–C(19) in β -position. Furthermore, the interaction Me(30)/ H_{β} -C(19) indicated that the CH₂(19) group was in β -position with respect to ring A, and hence OH–C(10) was in α -position. In addition, The NOESY correlations Me(18)/ H-C(20), $H-C(17)/CH_2(22)$, $H-C(16)/CH_2(22)$ confirmed the configuration at C(20) as (R) [17–19]. Thus, the structure of 1 was established as $(3\beta, 6\alpha, 10\alpha, 16\beta, 24E)$ -3,6-

	1	2	3	4
$CH_2(1)$	$1.87 - 1.95 (m, H_a),$	$1.80 - 1.87 \ (m, H_a),$	$1.32 - 1.40 \ (m, H_a),$	$1.90-1.96 (m, H_a),$
	$1.87 - 1.95 \ (m, H_{\beta})$	$1.80 - 1.87 \ (m, H_{eta})$	$1.32 - 1.40 \ (m, H_{eta})$	$1.90 - 1.96 \ (m, H_{\beta})$
$CH_2(2)$	$1.71 - 1.79 \ (m, H_a),$	$1.70 - 1.77 \ (m, { m H}_a),$	$1.67 - 1.74 \ (m, H_{a}),$	$1.73 - 1.80 \ (m, H_a),$
	$1.93 - 1.98 \ (m, H_{eta})$	$1.85 - 1.90 \ (m, H_{\beta})$	$1.86 - 1.93 \ (m, H_{eta})$	$1.93 - 1.98 \ (m, H_{\beta})$
H-C(3)	$4.93 \ (dd, J = 10.4, 2.6)$	$4.93 \ (dd, J = 9.5, 4.2)$	$4.86 \ (dd, J = 11.6, 4.0)$	$4.95 \ (dd, J = 9.3, 2.0)$
H-C(5)	2.32 (d, J = 6.9)	2.33 (d, J = 6.2)	$2.42 \ (d, J = 6.8)$	$2.30 \ (d, J = 6.1)$
H-C(6)	5.58 - 5.62 (m)	$5.61 \ (ddd, J=11.0, 6.2, 4.3)$	$5.49 \ (ddd, J = 11.6, 6.8, 2.4)$	5.50-5.56(m)
$CH_2(7)$	$1.88 - 1.95 (m, H_a),$	$1.71 - 1.77 \ (m, H_a),$	$2.15 - 2.21 \ (m, H_a),$	$1.78 - 1.83 (m, H_a),$
	$1.88 - 1.95 \ (m, H_{\beta})$	$1.71 - 1.77 \ (m, H_{\beta})$	$3.12 \ (dt, J = 9.5, 6.0, H_{\beta})$	$1.78 - 1.83 \ (m, H_{eta})$
H-C(8)	2.97 (br. $d, J = 11.7$)	3.04 (br. d, J = 10.2)	2.32 - 2.39 (m)	2.46 (br. $d, J = 11.4$)
H-C(11)	5.92 (br. s)	6.03 (br. s)	5.75 (d, J = 9.9)	$5.46 \ (dd, J = 3.8, 1.2)$
H-C(12)	1	I	$6.40 \ (d, J = 9.9)$	2.04-2.31 (m)
or $CH_2(12)$				
$CH_{2}(15)$	2.29 $(dd, J = 14.3, 6.1, H_a)$,	$2.30 (d, J = 17.5, H_a),$	$2.00-2.05 \ (m, H_a),$	2.20 $(d, J = 19.0, H_a)$,
	2.38 $(dd, J = 14.3, 7.6, H_{\beta})$	$2.71 (d, J = 17.5, \mathrm{H}_{eta})$	$2.35 - 2.41 \ (m, H_{\beta})$	2.40 $(d, J = 19.0, H_{\beta})$
H-C(16)	$4.66 \ (ddd, J=7.9, 7.6, 6.1)$		$4.82 \ (ddd, J=7.3, 6.4, 6.3)$	
H-C(17)	$2.50 \ (dd, J = 10.7, 7.9)$	2.98 (d, J = 5.0)	$2.30 - 2.36 \ (m)$	2.37 (d, J = 9.5)
Me(18)	1.55(s)	1.35(s)	1.43 (s)	0. 93 (s)
$CH_2(19)$	$2.73 - 2.77 (m, H_a),$	2.73 $(dd, J = 15.2, 1.2, H_a)$,	$2.00 - 2.05 \ (m, H_a),$	$2.65 \ (dd, J = 15.0, 1.2, H_a),$
	$3.12 \text{ (br. } d, J = 14.8, H_{eta})$	$3.20 \ (dd, J = 15.2, 1.2, H_{\beta})$	$2.27 \ (dd, J = 14.3, 1.0, H_{eta})$	2.98 $(dd, J = 15.0, 1.2, H_{\beta})$
H-C(20)	2.28-2.34(m)	$1.95 - 2.20 \ (m)$	2.37 - 2.43 (m)	$1.83 - 1.89 \ (m)$
Me(21)	1.38 $(d, J = 6.5)$	$1.30 \ (d, J = 6.8)$	$1.19 \ (d, J = 6.6)$	$1.01 \ (d, J = 6.8)$
$CH_2(22)$	1.32 - 1.38 (m),	1.60 - 1.67 (m),	1.28 - 1.35 (m),	$1.39 - 1.44 \ (m),$
	2.11 - 2.16 (m)	1.82 - 1.89(m)	2.04 - 2.30 (m)	2.10-2.17 (m)
$CH_2(23)$	2.20-2.27 (m),	2.09-2.16(m),	2.12 - 2.19 (m),	2.11-2.17(m),
	2.31 - 2.37 (m)	2.20-2.26(m)	2.29 - 2.35 (m)	2.18-2.25(m)
H-C(24)	5.72 (t, J = 6.4)	5.66(t, J = 6.6)	5.72 (t, J = 6.4)	5.71 (t, J = 6.3)
$CH_2(26)$	4.21 (d, J = 11.4),	4.23 (d, J = 11.5),	$4.24 \ (d, J = 11.6),$	4.26 $(d, J = 11.3)$,
	4.48~(d, J = 11.4)	4.50 (d, J = 11.5)	4.51 (d, J = 11.6)	4.52 (d, J = 11.3)
Me(27)	1.78(s)	1.78(s)	1.80(s)	1.83(s)
Me(28)	0.91(s)	1.07(s)	1.27(s)	1.04(s)
Me(29)	1.08(s)	1.07 (s)	1.05(s)	1.04(s)

Table 1. ¹*H-NMR Data* (500 MHz, C₅D₅N) of Compounds **1**-4. ô in ppm, J in Hz.

2242

Helvetica Chimica Acta – Vol. 94 (2011)

	1	2	3	4
Me(30)	1.20(s)	1.21 (s)	1.15 (s)	1.21(s)
AcO-C(3)	2.06(s)	2.08(s)	2.08(s)	2.06(s)
AcO-C(6)	2.08(s)	2.08(s)	2.03(s)	2.08(s)
H-C(1')	$4.90 \ (d, J = 7.8)$	4.90 (d, J = 7.9)	4.92 (d, J = 7.6)	4.93 (d, J = 7.5)
H-C(2')	4.09 (t, J = 7.8)	4.08(t, J = 7.9)	4.09 (t, J = 7.6)	4.10(t, J = 7.5)
H-C(3')	4.26 - 4.33 (m)	$4.25 - 4.32 \ (m)$	4.26 - 4.33 (m)	$4.24 - 4.32 \ (m)$
H–C(4')	4.26 - 4.33 (m)	4.25 - 4.32 (m)	4.26 - 4.33 (m)	$4.24 - 4.32 \ (m)$
H-C(5')	$3.94 - 4.01 \ (m)$	3.92 - 4.00 (m)	3.92 - 4.00 (m)	3.90 - 3.99 (m)
$CH_2(6')$	4.57 (dd, J = 11.7, 2.0),	4.57 (dd, J = 11.7, 2.0),	4.57 (dd, J = 11.9, 2.0),	$4.57 \ (dd, J = 11.5, 2.0),$
	$4.41 \ (dd, J = 11.7, 4.6)$	$4.40 \ (dd, J = 11.7, 5.0)$	$4.40 \ (dd, J = 11.9, 5.5)$	$4.41 \ (dd, J = 11.5, 4.6)$

	1	2	3	4
C(1)	44.5 (<i>t</i>)	44.2 (<i>t</i>)	30.1 (<i>t</i>)	44.5 (<i>t</i>)
C(2)	25.3(t)	25.2(t)	25.3(t)	25.0(t)
C(3)	79.5(d)	79.4(d)	80.0(d)	79.7(d)
C(4)	39.5 (s)	39.5 (s)	40.4(s)	39.5 (s)
C(5)	57.9 (d)	57.8 (d)	60.8(d)	58.0(d)
C(6)	76.0(d)	75.5 (<i>d</i>)	75.6(d)	76.6(d)
C(7)	32.9(t)	33.3(t)	27.9(t)	33.0(t)
C(8)	45.8 (<i>d</i>)	44.4(d)	42.3 (<i>d</i>)	42.5(d)
C(9)	157.6 (s)	159.9 (s)	76.0(s)	137.4 (s)
C(10)	72.3 (s)	72.3(s)	73.2 (s)	72.3(s)
C(11)	128.3 (d)	127.7 (d)	133.4 (<i>d</i>)	123.9 (d)
C(12)	203.8 (s)	201.8 (s)	136.7 (d)	36.4 (<i>t</i>)
C(13)	58.0 (s)	57.3 (s)	47.5 (s)	44.4 (s)
C(14)	50.7 (s)	46.2 (s)	49.9 (s)	42.5 (s)
C(15)	46.7 (<i>t</i>)	48.6 (<i>t</i>)	45.1 (<i>t</i>)	48.9 (<i>t</i>)
C(16)	70.3(d)	216.0 (s)	71.4(d)	217.6 (s)
C(17)	49.5 (d)	55.8(d)	52.2(d)	60.5(d)
C(18)	14.3(q)	15.6(q)	21.8(q)	16.2(q)
C(19)	48.4 (<i>t</i>)	48.5 (<i>t</i>)	49.9 (<i>t</i>)	48.7 (<i>t</i>)
C(20)	30.6(d)	32.3(d)	31.1 (<i>d</i>)	31.9 (<i>d</i>)
C(21)	19.7(q)	20.9(q)	18.5(q)	18.8(q)
C(22)	36.9 (<i>t</i>)	34.9 (<i>t</i>)	36.5 (<i>t</i>)	35.6 (<i>t</i>)
C(23)	26.0 (t)	26.4 (<i>t</i>)	25.6 (t)	25.8 (t)
C(24)	129.5 (d)	128.4(d)	129.4 (d)	128.7(d)
C(25)	131.9 (s)	132.5 (s)	132.0 (s)	132.7 (s)
C(26)	75.2 (<i>t</i>)	75.2 (<i>t</i>)	75.3 (<i>t</i>)	75.2 <i>(t)</i>
C(27)	14.2(q)	14.2(q)	14.3(q)	14.2(q)
C(28)	19.4(q)	18.2(q)	21.3(q)	18.2(q)
C(29)	28.4(q)	27.9(q)	27.1(q)	28.4(q)
C(30)	18.9(q)	18.4(q)	18.0(q)	18.8(q)
AcO-C(3)	21.7(q), 170.4(s)	21.6(q), 170.4(s)	21.5(q), 170.5(s)	21.7 (q), 170.4 (s)
AcO-C(6)	21.1(q), 170.5(s)	21.0(q), 170.5(s)	21.0(q), 170.0(s)	21.1(q), 170.5(s)
C(1')	103.6(d)	103.8(d)	103.9 (<i>d</i>)	103.6 (<i>d</i>)
C(2')	75.2 (<i>d</i>)	75.3 (d)	75.3 (d)	75.5 (<i>d</i>)
C(3')	78.7(d)	78.6(d)	78.7(d)	78.8(d)
C(4′)	71.8(d)	72.0(d)	71.9 (<i>d</i>)	71.8(d)
C(5′)	78.5(d)	78.6(d)	78.7(d)	78.5(d)
C(6')	62.9 (<i>t</i>)	62.8(t)	63.0 (<i>t</i>)	62.9 (<i>t</i>)

Table 2. ¹³C-NMR Data (125 MHz, C₅D₅N) of Compounds 1-4. δ in ppm.

bis(acetyloxy)-10,16-dihydroxy-12-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside¹).

Compound 2, named huangqiyenin H, was obtained as a white amorphous powder, with a molecular formula $C_{40}H_{60}O_{13}$ based on the HR-FAB-MS (m/z 771.3936 ($[M + Na]^+$)). The ¹H-NMR spectrum (*Table 1*) showed seven Me *s*, a Me *d*, and two olefinic H-atom signals at $\delta(H)$ 6.03 (br. *s*) and 5.66 (J = 6.6 Hz). The ¹³C-NMR spectrum (*Table 2*) revealed 40 C-atoms including two ketonic C=O groups at $\delta(C)$ 216.0 and 201.8, four olefinic C-atoms at $\delta(C)$ 127.7, 128.4, 132.5, and 159.9, two Ac

groups at $\delta(C)$ 21.6, 170.4, 21.0, and 170.5, and a glucosyl group at $\delta(C)$ 103.8, 75.3, 78.6, 72.0, 78.6, and 62.8. The acid hydrolysis of **2** gave D-glucose [16]. Detailed comparison of the ¹H- and ¹³C-NMR data of **2** and **1** indicated they have identical rings A - C and side chain but a different ring D. The appearance of a C=O signal at $\delta(C)$ 216.0 in the ¹³C-NMR spectrum of **2** and the disappearance of the signal of H–C(16) in the ¹H-NMR spectrum revealed the presence of a C=O group at C(16), which was further confirmed by the HMBC data. The HMBCs H_a–C(15)/C(13), C(14), C(16), and C(17), and H–C(20)/C(13), C(16), and C(17) confirmed the connectivity of ring D. Therefore, **2** was elucidated as $(3\beta,6\alpha,10\alpha,24E)$ -3,6-bis(acetyloxy)-10-hydroxy-12,16dioxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside¹).

Huangqiyenin I (3) was obtained as a white amorphous powder, and the molecular formula was determined as $C_{40}H_{64}O_{13}$, on the basis of the HR-FAB-MS (m/z 775.4249 $([M + Na]^+))$. The acid hydrolysis of **3** liberated D-glucose, which was identified by GC analysis [16]. The ¹H-NMR spectrum (*Table 1*) showed the presence of three olefinic H-atoms at $\delta(H)$ 6.40 (J=9.9 Hz), 5.75 (J=9.9 Hz), and 5.72 (J=6.4 Hz), of seven tertiary Me groups at $\delta(H)$ 1.05, 1.15, 1.27, 1.43, 1.80, 2.03, and 2.08, and of a secondary Me group at $\delta(H)$ 1.19 (J = 6.6 Hz). In the ¹³C-NMR spectrum (Table 2), the 40 Catoms were assigned to eight Me, nine CH_2 , and 15 CH groups and to eight quaternary C-atoms by a DEPT experiment. The spectroscopic data of **3** were similar to those of huangqiyenin F [12]. However, olefinic H-atoms of a disubstituted C=C bond were observed in the ¹H-NMR spectrum of **3**. In the HMBC spectrum, the correlation of the olefinic H–C(12) to C(9), C(11), C(13), and C(14), of H–C(11) to C(8), C(9), C(12), and C(13), and of Me(18) to C(12), C(13), C(14), and C(17) indicated that the C=C bond is located between C(11) and C(12) (*Fig.*). The key NOE correlations H_{β} -C(19)/ Me(30), H_{β} -C(19)/H-C(6), H_{β} -C(19)/H-C(8), and H-C(6)/H-C(8) indicated that $CH_2(19)$ was in β -orientation with respect to ring A, and the OH groups at C(9) and C(10) were α -orientated. The configuration at C(20) was determined as (R) by the NOESY correlations Me(18)/H-C(20), $H-C(17)/CH_2(22)$, and H-C(12)/Me(21)[17–19]. Accordingly, compound **3** was assigned as $(3\beta, 6\alpha, 9\alpha, 10\alpha, 16\beta, 24E)$ -3,6bis(acetyloxy)-9,10,16-trihydroxy-9,19-cyclo-9,10-secolanosta-11,24-dien-26-yl β -D-glucopyranoside¹).

Huangqiyenin J (4) was obtained as a white amorphous powder. The molecular formula was determined as $C_{40}H_{62}O_{12}$ by positive-mode HR-FAB-MS (m/z 757.4114 ($[M + Na]^+$)). The ¹H-NMR spectrum of 4 (*Table 1*) showed seven Me *s* at $\delta(H)$ 0.93, 1.04 (6 H), 1.21, 1.83, 2.06, and 2.08, a Me *d* at $\delta(H)$ 1.01 (J = 6.8 Hz), and two olefinic H-atom signals at $\delta(H)$ 5.46 (J = 3.8, 1.2 Hz) and 5.71 (J = 6.3 Hz). The ¹³C-NMR spectrum (*Table 2*) exhibited 40 C-atoms including four olefinic C-atoms at $\delta(C)$ 123.9, 128.7, 132.7, and 137.4, and three C=O groups at $\delta(C)$ 170.4, 170.5, and 217.6. The acid hydrolysis of 4 gave D-glucose [16]. Comparison of the ¹H- and ¹³C-NMR data of 4 with those of huangqiyenin F [12] and 2 showed that 4 has the same rings A - C as huangqiyenin F, and the same ring D and side-chain moiety as 2, which was further established by the key HMBC, HSQC-TOCSY, and NOESY features. The key HMBC cross-peaks Me(18)/C(12), C(13), C(14), and C(17), and Me(28)/C(8), C(13), C(14), and C(15) indicated the connection between ring C and D. Thus, 4 was established as ($3\beta, 6\alpha, 10\alpha, 24E$)-3,6-bis(acetyloxy)-10-hydroxy-16-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-glucopyranoside¹).

Experimental Part

General. Column chromatography (CC): silica gel 60 (SiO₂; 200–300 mesh; Merck, Germany). HPLC: Waters-Delta-600 pump and Waters-2414 refractive-index detector; TSK-gel ODS-120T column (10 µm, 40 × 300 mm; Tosoh, Japan). GC: Fuli-9790 H₂ flame detector; DM-5 column (0.25 µm, 30 m × 0.25 mm; Dikma, China). IR Spectra: Shimadzu FI-IR-8100 spectrometer; $\tilde{\nu}$ in cm⁻¹. NMR Spectra: JNM-LA-500 spectrometer; δ in ppm rel. to Me₄Si as internal standard, J in Hz. HR-FAB-MS: Jeol-JMS-DX-302 mass spectrometer; in m/z.

Plant Material. The leaves of *A. membranaceus* BUNGE were collected in Daxing'anling, Heilongjiang Province, P. R. China, in August 1995, and identified by Prof. *Zhenyue Wang*, Heilongjiang University of Chinese Medicine, P. R. China. A voucher specimen (No. 19950026) is deposited with the Herbarium of Heilongjiang University of Chinese Medicine, P. R. China.

Extraction and Isolation. The dried leaves of *A. membranaceus* BUNGE (1.2 kg) were defatted with petroleum ether (2×51) for 2 h each time (80°) . Then, the residue was extracted with MeOH under reflux (3×51) for 3 h each time, and the extract was concentrated to a syrup. A suspension of the MeOH extract (310 g) in H₂O (51) was extracted with BuOH (3×51) sat. with H₂O. The BuOH layer was concentrated to give the BuOH extract (119 g). The BuOH extract (60 g) was subjected to CC (SiO₂, CHCl₃/MeOH/H₂O 6:1:0.1 and then CHCl₃/MeOH/H₂O 3:1:0.1): *Fractions I*–*X*, in order of elution. *Fr. IV* (6.8 g) was resubjected to CC (SiO₂, CHCl₃/MeOH/H₂O 3:7): **1** (123 mg; t_R 9.0 min), **2** (42.1 mg; t_R 14.5 min), **4** (30.4 mg; t_R 19.3 min), and **3** (80.8 mg; t_R 25.1 min).

Acid Hydrolysis of 1–4. Each of compounds 1–4 (each 4 mg) was hydrolyzed in 1M HCl (1.0 ml) for 2 h at 85°. The mixture was cooled and partitioned between CHCl₃ (2.0 ml) and H₂O (2.0 ml). The aq. layer was washed with CHCl₃ (3 × 3.0 ml), neutralized with Ba(OH)₂, filtered, and evaporated. The residue was dissolved in pyridine (1.0 ml), and 0.1M L-cysteine methyl ester hydrochloride in pyridine (2.0 ml) was added. The mixture was heated at 60° for 1 h. An equal volume of Ac₂O was added under heating, and incubation was continued for 1 h. The acetylated thiazolidine derivatives was compared with authentic samples by GC (*DM-5* column; injector and detector temp. 280°; temp. gradient for the oven from at 160° to 195° at a rate of 5°/min). The sugar unit in compounds 1–4 was determined by the retention time t_R of the peak of the hydrolysates and that of an authentic sample of D-glucose (t_R 15.1 min).

Huangqiyenin G (=(3 β ,6a,10a,16 β ,24E)-3,6-*Bis*(acetyloxy)-10,16-dihydroxy-12-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-*Glucopyranoside* = (2E,6R)-6-[2S,3R,3aR,6aR,9S,10aR,11S, 12aR,12bS)-9,11-*Bis*(acetyloxy)-1,2,3,3a,4,6,6a,7,8,9,10,10a,11,12,12a,12b-hexadecahydro-2,6a-dihydroxy-3a,10,10,12b-tetramethyl-4-oxobenzo[4,5]cyclohept[1,2-e]inden-3-yl]hex-2-en-1-yl β -D-*Glucopyranoside*; **1**): White amorphous powder. [a]₂₁²¹ = +55.1 (*c* = 1.0, MeOH). IR (KBr): 3430, 2959, 1729, 1713, 1658, 1371, 1078, 1022. ¹H- and ¹³C-NMR: *Tables 1* and 2. FAB-MS (neg.): 749 ([M - H]⁻). HR-FAB-MS (pos.): 773.4085 ([M + Na]⁺, C₄₀H₆₂NaO₁₃; calc. 773.4088).

Huangqiyenin H (=(3β,6a,10a,24E)-3,6-Bis(acetyloxy)-10-hydroxy-12,16-dioxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β-D-Glucopyranoside = (2E,6R)-6-[3R,3aR,6aR,9S,10aR,11S,12aR,12bS)-9,11-Bis(acetyloxy)-1,2,3,3a,4,6,6a,7,8,9,10,10a,11,12,12a,12b-hexadecahydro-6a-hydroxy-3a,10,10,12btetramethyl-2,4-dioxobenzo[4,5]cyclohept[1,2-e]inden-3-yl]hex-2-en-1-yl β-D-Glucopyranoside; **2**): White amorphous powder. [a]₂₁²¹ = +61.5 (c = 1.0, MeOH). IR (KBr): 3425, 2945, 1745, 1729, 1713, 1650, 1078, 1022. ¹H- and ¹³C-NMR: *Tables 1* and 2. FAB-MS (pos.): 748 (M^+), 771 ([M + Na]⁺). HR-FAB-MS (pos.): 771.3936 ([M + Na]⁺, C₄₀H₆₀NaO₁₃; calc. 771.3932).

Huangqiyenin I (=(3 β ,6 α ,10 α ,16 β ,24E)-3,6-Bis(acetyloxy)-9,10,16-trihydroxy-9,19-cyclo-9,10-secolanosta-11,24-dien-26-yl β -D-Glucopyranoside = (2E,6R)-6-[2S,3R,3aR,5aR,6aR,9S,10aR,11S,12aR, 12bS)-9,11-Bis(acetyloxy)-1,2,3,3a,5a,6,6a,7,8,9,10,10a,11,12,12a,12b-hexadecahydro-2,5a,6a-trihydroxy-3a,10,10,12b-tetramethylbenzo[4,5]cyclohept[1,2-e]inden-3-yl]hex-2-en-1-yl β -D-Glucopyranoside; **3**): White amorphous powder. [α]₂₁²¹ = +65.3 (c =1.0, MeOH). IR (KBr): 3440, 2943, 1719, 1709, 1079, 1026. ¹H- and ¹³C-NMR: Tables I and 2. FAB-MS (neg.): 751 ([M – H]⁻). HR-FAB-MS (pos.): 775.4249 ([M + Na]⁺, C₄₀H₆₄NaO₁₃; calc. 775.4245). Huangqiyenin J (=(3 β ,6 α ,10 α ,24E)-3,6-Bis(acetyloxy)-10-hydroxy-16-oxo-9,19-cyclo-9,10-secolanosta-9(11),24-dien-26-yl β -D-Glucopyranoside = (2E,6R)-6-[3R,3aR,5aR,6aR,9S,10aR,11S,12aR, 12bS)-9,11-Bis(acetyloxy)-1,2,3,3a,4,6,6a,7,8,9,10,10a,11,12,12a,12b-hexadecahydro-5a-hydroxy-3a,10, 10,12b-tetramethyl-2-oxobenzo[4,5]cyclohept[1,2-e]inden-3-yl]hex-2-en-1-yl β -D-Glucopyranoside; **4**): White amorphous powder. [a]₂₁²¹ = +69.6 (c = 1.0, MeOH). IR (KBr): 3441, 2938, 17.44, 1720, 1715, 1080, 1026. ¹H- and ¹³C-NMR: *Tables 1* and 2. FAB-MS (neg.): 733 ([M – H]⁻). HR-FAB-MS (pos.): 757.4143 ([M+Na]⁺, C₄₀H₆₂NaO₁₂; calc. 757.4139).

REFERENCES

- [1] Y. Zhang, Z. Han, L. Liu, Chin. Wild Plant Resour. 2003, 22, 40.
- [2] Y. Zhang, J. Li, H. Sun, M. Su, J. Chin. Med. Mater. 2007, 30, 1433.
- [3] H. Liu, W. Wei, W.-y. Sun, X. Li, J. Ethnopharmacol. 2009, 122, 502.
- [4] W.-D. Zhang, H. Chen, C. Zhang, R.-H. Liu, H.-L. Li, H.-Z. Chen, *Planta Med.* 2006, 72, 4.
 [5] X. Yin, Y. Zhang, H. Wu, X. Zhu, X. Zheng, S. Jiang, H. Zhuo, J. Shen, L. Li, J. Qiu, *J. Pharmacol.*
- *Sci.* **2004**, *95*, 256. [6] W.-J. Zhang, P. Hufnagl, B. R. Binder, J. Wojta, *Thromb. Haemost.* **2003**, *90*, 904.
- [7] A. Navarrete, J. Arrieta, L. Terrones, H. Abou-Gazar, I. Calis, J. Pharm. Pharmacol. 2005, 57, 1059.
- [8] Y. Luo, Z. Qin, Z. Hong, X. Zhang, D. Ding, J.-H. Fu, W.-D. Zhang, J. Chen, *Neurosci. Lett.* 2004, 97, 1057.
 - 363. 218.
- [9] Y. Ma, Z. Tian, H. Kuang, C. Yuan, L. Liu, Acta Bot. Sin. 1993, 35, 480.
- [10] H. Kuang, N. Zhang, Z. Tian, P. Zhang, Y. Okada, T. Okuyama, Nat. Med. 1997, 51, 358.
- [11] Y. Ma, Z. Tian, H. Kuang, C. Yuan, C. Shao, K. Ohtani, R. Kasai, O. Tanaka, Y. Okada, T. Okuyama, *Chem. Pharm. Bull.* 1997, 45, 359.
- [12] H. Kuang, Y. Okada, B. Yang, Z. Tian, T. Okuyama, Helv. Chim. Acta 2009, 92, 950.
- [13] M. I. Choudhary, S. Shahnaz, S. Parveen, A. Khalid, S. A. M. Ayatollahi, Atta-ur-Rahman, M. Parvez, J. Nat. Prod. 2003, 66, 739.
- [14] Atta-ur-Rahman, A. Ata, S. Naz, M. I. Choudhary, B. Sener, S. Turkoz, J. Nat. Prod. 1999, 62, 665.
- [15] S. Kadota, J. X. Li, K. Tanaka, T. Namba, *Tetrahedron* 1995, 51, 1143.
- [16] C. Yang, Q. An, Z. Xiong, Y. Song, K. Yu, F. Li, Planta Med. 2009, 75, 656.
- [17] A. S. Antonov, S. S. Afiyatullov, A. I. Kalinovsky, L. P. Ponomarenko, P. S. Dmitrenok, D. L. Aminin, I. G. Agafonova, V. A. Stonik, J. Nat. Prod. 2003, 66, 1082.
- [18] A. S. Antonov, A. I. Kalinovsky, V. A. Stonik, S. S. Afiyatullov, D. L. Aminin, P. S. Dmitrenok, E. Mollo, G. Cimino, J. Nat. Prod. 2007, 70, 169.
- [19] T. A. Mansoor, J. Hong, C.-O. Lee, S.-J. Bae, K. S. Im, J. H. Jung, J. Nat. Prod. 2005, 68, 331.

Received April 28, 2011